Check the source before applying its dose
Twelve findings are listed. The v7.3 addition concerns an atenolol mirror with an IV product heading and oral dosing text. All eleven prior findings remain available.
No preserved source text was deleted or silently rewritten. Correctly scoped official evidence remains available. The exclusions below concern new imports from the identified pages, not all records for a generic drug.
ZELAPAR page contains GAMMAGARD clinical passages
The description names selegiline ODT, but indications and IV/SC dosing include GAMMAGARD. Other parts return to selegiline.
Clinical handling: Do not use this mirror as a clean dosing source; use the matched official ZELAPAR label.
Import handling: Clinical text from this page was excluded from new import.
XOPENEX solution page includes HFA inhaler dosing
Nebulized-solution description is mixed with metered-dose HFA instructions. This finding does not invalidate the separately scoped HFA source.
Clinical handling: Use the exact nebulized or HFA label; do not transfer inhaler actuations to nebulizer solution.
Import handling: Clinical text from this page was excluded from new import.
ZITHROMAX page mixes oral description and IV instructions
The description discusses oral tablets/packets, while returned dosing and indications discuss IV treatment.
Clinical handling: Do not import this mixed-route page as one renal protocol; confirm exact azithromycin formulation and route.
Import handling: Clinical text from this page was excluded from new import.
YUTREPIA mirror describes treprostinil injection
The directory and returned mirror identify injection and infusion instructions, whereas official YUTREPIA is inhalation powder.
Clinical handling: Exclude the mirror clinical text from new import; use the inhalation-powder label and device instructions.
Import handling: Clinical text from this page was excluded from new import.
ZEMPLAR directory tablet wording does not match IV content
The index describes tablets, but the selected monograph contains IV dosing. The separately scoped IV summary is retained with this warning.
Clinical handling: Identify formulation from the product label, not the directory wording. Adult IV titration must not be replaced by the pediatric increment.
Import handling: A selected, explicitly scoped summary is retained with the inconsistency disclosed.
Amoxicillin label Highlights conflicts with full renal section
Highlights says severe impairment with GFR greater than 30, while full section 2.5 prohibits 875 mg below 30 and provides lower-GFR adjustment rows.
Clinical handling: The v7.1 card explicitly uses full section 2.5/Table 2, not the contradictory Highlights line. Verify the full label and selected strength.
Import handling: A selected, explicitly scoped summary is retained with the inconsistency disclosed.
SOTYKTU mirror: malformed PK renal boundary
The retrieved PK paragraph prints a lower bound of 260 for the mild-renal range. That numerical passage was not imported.
Clinical handling: Use the intact explicit renal-use paragraph and primary label; do not repair the number by guessing.
Import handling: A selected, explicitly scoped summary is retained with the inconsistency disclosed.
VYVGART mirror: inconsistent BSA indexing text
A supporting PK passage prints 1.72 m2 while the renal-use section and primary label specify 1.73 m2.
Clinical handling: The selected summary follows the intact renal-use section and primary label; do not use the malformed unit as a new measure.
Import handling: A selected, explicitly scoped summary is retained with the inconsistency disclosed.
SAVELLA mirror: missing separator in PK range
The retrieved PK text renders the moderate-impairment range as 3049 mL/min. The intact renal-dosing section is summarized instead.
Clinical handling: Do not interpret 3049 as a renal threshold; use the product label and intact dosing section.
Import handling: A selected, explicitly scoped summary is retained with the inconsistency disclosed.
EXBLIFEP: archived-label currency and method/units
The checked FDA source is the 2024 approval label. Its table names MDRD but prints mL/min without an indexing explanation; Highlights uses >130 while the detailed table uses >=130.
Clinical handling: Detailed Table 1 controls the >=130 infusion boundary. Confirm current product labeling and local renal-method policy before use.
Import handling: A selected, explicitly scoped summary is retained with the inconsistency disclosed.
FRUZAQLA: quantitative table versus warning-section shorthand
The proteinuria warning says recovery to <=Grade 1, whereas the dose-modification table specifies full resolution or <1 g/24 hours and additional stop criteria.
Clinical handling: Use the quantitative table for the source-bound summary; retain the difference and do not substitute the baseline PK finding for toxicity management.
Import handling: A selected, explicitly scoped summary is retained with the inconsistency disclosed.
Atenolol mirror mixes an IV heading with oral instructions
The product description names Tenormin I.V. Injection; the renal passage includes oral dose maxima. The route must be verified independently before use.
Clinical handling: Use a matched oral or IV label for the prescribed route. The mixed mirror was excluded from this release.
Import handling: Clinical text from this page was excluded from new import.
Missing text is a separate issue
The retrieved ZUSDURI RX text did not include a usable renal section. Its new product record therefore uses the official intravesical label, without inventing an RX renal recommendation. Partial WAYRILZ and YEZTUGO mirror returns are labeled as PK-only evidence; official renal use sections are presented separately.